Log In
BCIQ
Print this Print this
 

setipiprant (KYTH-105) (formerly ACT-129968)

Also known as: CRTH2 antagonist

  Manage Alerts
Collapse Summary General Information
Company Actelion Ltd.
DescriptionOral prostaglandin D2 (PGD2) receptor (CRTH2) antagonist
Molecular Target Prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2) (CRTH2) (GPR44) (DP2) (CD294)
Mechanism of ActionProstaglandin D2 (PGD2) receptor subtype DP2 (CRTH2) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationAlopecia
Indication DetailsTreat androgenic alopecia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$27.0M

$1.5M

$25.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/10/2015

$27.0M

$1.5M

$25.5M

Get a free BioCentury trial today